^99mTc-PSMA-SPECT/CT zur Diagnostik des Prostatakarzinoms

Zusammenfassung

Neben den klinisch bereits etablierten PET-kompatiblen PSMA-Radioliganden stehen seit kurzer Zeit mit ^99 mTc gekoppelte SPECT-kompatible PSMA-Radioliganden zur Diagnostik des Prostatakarzinoms zur Verfügung. Aufgrund der hohen Nachfrage nach PSMA-basierter Hybridbildgebung könnten diese für bestimmte Indikationen eine diagnostische Alternative darstellen, insbesondere sofern keine PET/CT verfügbar ist. Der folgende Artikel soll eine Übersicht über die vorliegende Evidenz und möglichen Einsatzmöglichkeiten der ^99 mTc-PSMA-SPECT/CT zur Diagnostik des Prostatakarzinoms geben.

Abstract

Besides the already clinically established PET-compatible PSMA-radioligands, SPECT-suitable PSMA-radioligands have been recently introduced for diagnosis of prostate cancer. Due to the high demand for PSMA-based hybrid imaging already leading to a capacity bottleneck, these could represent an alternative for selected indications. The following article gives an overview regarding the existing evidence and possible applications of ^99 mTc-PSMA SPECT/CT for the diagnosis of prostate cancer.

Schlüsselwörter

Prostatakrebs - PSMA - SPECT/CT - Hybridbildgebung

Keywords

Prostate cancer - PSMA - SPECT/CT - Hybrid imaging

Publication History

Article published online:
30 November 2020

• Literatur

• 1 Goffin KE, Joniau S, Tenke P. et al. Phase 2 study of 99mTc-Trofolastat SPECT/CT to identify and localize prostate cancer in intermediate-and high-risk patients undergoing radical prostatectomy and extended pelvic LN dissection. Journal of Nuclear Medicine 2017; 58: 1408-1413
• 2 Schmidkonz C, Cordes M, Beck M. et al. SPECT/CT with the PSMA ligand 99mTc-MIP-1404 for whole-body primary staging of patients with prostate cancer. Clinical nuclear medicine 2018; 43: 225-231
• 3 Lawal IO, Ankrah AO, Mokgoro NP. et al. Diagnostic sensitivity of Tc‐99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga‐68 PSMA PET/CT. The Prostate 2017; 77: 1205-1212
• 4 Schmidkonz C, Hollweg C, Beck M. et al. 99mTc‐MIP‐1404‐SPECT/CT for the detection of PSMA‐positive lesions in 225 patients with biochemical recurrence of prostate cancer. The Prostate 2018; 78: 54-63
• 5 Eiber M, Maurer T, Souvatzoglou M. et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. Journal of Nuclear Medicine 2015; 56: 668-674
• 6 Ceci F, Uprimny C, Nilica B. et al. 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?. European journal of nuclear medicine and molecular imaging 2015; 42: 1284-1294
• 7 Afshar-Oromieh A, Avtzi E, Giesel FL. et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. European journal of nuclear medicine and molecular imaging 2015; 42: 197-209
• 8 Perera M, Papa N, Roberts M. et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. European urology 2019; 77: 403-417
• 9 Liu C, Zhu Y, Su H. et al. Relationship between PSA kinetics and Tc‐99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy. The Prostate 2018; 78: 1215-1221
• 10 Su H-C, Zhu Y, Ling G-W. et al. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse. Asian journal of andrology 2017; 19: 267
• 11 Rauscher I, Maurer T, Souvatzoglou M. et al. Intrapatient comparison of 111In-PSMA I&T SPECT/CT and hybrid 68Ga-HBED-CC PSMA PET in patients with early recurrent prostate cancer. Clinical nuclear medicine 2016; 41: e397-e402
• 12 Schmidkonz C, Goetz TI, Kuwert T. et al. PSMA SPECT/CT with 99m Tc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels. Annals of nuclear medicine 2019; 33: 891-898
• 13 Schmidkonz C, Cordes M, Beck M. et al. Assessment of Treatment Response by 99mTc-MIP-1404 SPECT/CT: A Pilot Study in Patients With Metastatic Prostate Cancer. Clinical nuclear medicine 2018; 43: e250-e258
• 14 Schmidkonz C, Atzinger A, Goetz TI. et al. 99mTc-MIP-1404 SPECT/CT for Patients With Metastatic Prostate Cancer: Interobserver and Intraobserver Variability in Treatment-Related Longitudinal Tracer Uptake Assessments of Prostate-Specific Membrane Antigen–Positive Lesions. Clinical Nuclear Medicine 2020; 45: 105-112
• 15 Rathke H, Afshar-Oromieh A, Giesel FL. et al. Intraindividual comparison of 99mTc-Methylene Diphosphonate and prostate-specific membrane antigen ligand 99mTc-MIP-1427 in patients with osseous metastasized prostate cancer. Journal of Nuclear Medicine 2018; 59: 1373-1379